Y0002236

Sorafenib for peak identification

European Pharmacopoeia (EP) Reference Standard

• Synonyma: Sorafenib tosylate, 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate, BAY 43-9006 tosylate salt, BAY43-9006 tosylate salt, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, 4-methylbenzenesulfonate
• Empirický vzorec (Hillův zápis): C₂₁H₁₆ClF₃N₄O₃·C₇H₈SO₃
• Číslo CAS: 475207-59-1
• Molekulová hmotnost: 637.03
• MDL number: MFCD08235032
• UNSPSC Code: 41116107
• NACRES: NA.24

Vlastnosti

• API family: sorafenib
• manufacturer/tradename: EDQM
• storage temp.: 2-8°C
• SMILES string: FC(F)(F)c2c(ccc(c2)NC(=O)Nc3ccc(cc3)Oc4cc(ncc4)C(=O)NC)Cl.[S](=O)(=O)([O-])c1ccc(cc1)C.[H+]
• InChI: 1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
• InChI key: IVDHYUQIDRJSTI-UHFFFAOYSA-N

Popis

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sorafenib for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Orally active kinase inhibitor that exerts anticancer efficacy via targeting Raf-1 (c-Raf), b-Raf, VEGFR-2 (Flk-1, KDR), VEGFR-3, PDGFR-β, Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Tosylate salt of the orally active kinase inhibitor Sorafenib (BAY 43-9006) that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Bezpečnostní informace

• pictograms: GHS08,GHS09
• signalword: Danger
• hcodes: H360FD,H362,H372,H410
• pcodes: P201 - P202 - P260 - P263 - P273 - P308 + P313
• Hazard Classifications: Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable